Armata Pharmaceuticals (ARMP) Non Operating Income (2013 - 2026)

Armata Pharmaceuticals has disclosed Non Operating Income across 14 years of filings, most recently posting -$106.6 million for Q1 2026.

• Non Operating Income for Q1 2026 came in at -$106.6 million, down 6519.34% year-over-year; the trailing twelve-month figure through Mar 2026 was -$245.4 million (down 713.86% YoY), and the FY2025 annual result was -$137.2 million, down 683.18% from the prior year.
• Non Operating Income came in at -$106.6 million for Q1 2026 at Armata Pharmaceuticals, up from -$110.5 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $20.9 million in Q2 2024 to a low of -$110.5 million in Q4 2025.
• The 5-year median for Non Operating Income is $1000.0 (2022), against an average of -$14.6 million.
• Peak annual rise in Non Operating Income reached 121540.0% in 2023, while the deepest fall reached 314500.0% in 2023.
• Armata Pharmaceuticals' Non Operating Income stood at $14000.0 in 2022, then sank by 73442.86% to -$10.3 million in 2023, then soared by 227.96% to $13.1 million in 2024, then tumbled by 940.82% to -$110.5 million in 2025, then advanced by 3.54% to -$106.6 million in 2026.
• The last three Non Operating Income figures came in at -$106.6 million (Q1 2026), -$110.5 million (Q4 2025), and -$18.9 million (Q3 2025), per Business Quant data.